Azitra (NYSEAMERICAN:AZTR – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04), FiscalAI reports.
Azitra Stock Performance
Shares of AZTR traded down $0.04 during trading hours on Friday, hitting $0.63. The stock had a trading volume of 54,689 shares, compared to its average volume of 1,532,242. Azitra has a 1-year low of $0.52 and a 1-year high of $3.91. The firm has a 50 day simple moving average of $1.72 and a 200-day simple moving average of $1.86.
Azitra Company Profile
Azitra, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapies for dermatological conditions. The company combines microbiology, genetic engineering and computational tools to identify and develop targeted treatments intended to address diseases affecting the skin. Azitra’s platform centers on engineered strains of beneficial skin bacteria and biologic compounds designed to deliver therapeutic proteins or otherwise influence the skin’s local environment. Its development programs have focused on conditions including inflammatory skin disorders, rare genetic diseases and treatment-related dermatologic complications.
Featured Stories
- Five stocks we like better than Azitra
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
- Firefly Aerospace Lights Up a High-Risk Space Opportunity
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
